Thomas J Cradick

List of Publications by Citations

34 papers	5,753 citations	20 h-index	34 g-index
34 ext. papers	6,685 ext. citations	9.5 avg, IF	5.38 L-index

#	Paper	IF	Citations
34	DNA targeting specificity of RNA-guided Cas9 nucleases. *Nature Biotechnology*, **2013**, 31, 827-32	44.5	3056
33	CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. *Nucleic Acids Research*, **2013**, 41, 9584-92	20.1	456
32	CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. *Nucleic Acids Research*, **2014**, 42, 7473-85	20.1	428
31	Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 9591-6	11.5	241
30	COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. *Molecular Therapy - Nucleic Acids*, **2014**, 3, e214	10.7	219
29	The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells. *Molecular Therapy*, **2016**, 24, 645-54	11.7	150
28	Streptococcus thermophilus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome. *Molecular Therapy*, **2016**, 24, 636-44	11.7	148
27	Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. *Nucleic Acids Research*, **2012**, 40, 5560-8	20.1	144
26	Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. *Molecular Therapy*, **2010**, 18, 947-54	11.7	142
25	TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. *Nucleic Acids Research*, **2014**, 42, 6762-73	20.1	130
24	Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. *Blood*, **2018**, 131, 1960-1973	2.2	110
23	An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. *Nucleic Acids Research*, **2014**, 42, e42	20.1	100
22	Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing. *Molecular Therapy*, **2016**, 24, 475-87	11.7	87
21	A Burden of Rare Variants Associated with Extremes of Gene Expression in Human Peripheral Blood. *American Journal of Human Genetics*, **2016**, 98, 299-309	11	61
20	Defining critical residues in the epitope for a HIV-neutralizing monoclonal antibody using phage display and peptide array technologies. *Gene*, **1993**, 137, 63-8	3.8	45
19	SAPTA: a new design tool for improving TALE nuclease activity. *Nucleic Acids Research*, **2014**, 42, e47	20.1	43
18	Efficient fdCas9 Synthetic Endonuclease with Improved Specificity for Precise Genome Engineering. *PLoS ONE*, **2015**, 10, e0133373	3.7	42

List of Publications

17	ZFN-site searches genomes for zinc finger nuclease target sites and off-target sites. *BMC Bioinformatics*, **2011**, 12, 152	3.6	34
16	TALENs Facilitate Single-step Seamless SDF Correction of F508del CFTR in Airway Epithelial Submucosal Gland Cell-derived CF-iPSCs. *Molecular Therapy - Nucleic Acids*, **2016**, 5, e273	10.7	32
15	Nanomedicine: tiny particles and machines give huge gains. *Annals of Biomedical Engineering*, **2014**, 42, 243-59	4.7	21
14	Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment Methods. *CRISPR Journal*, **2020**, 3, 440-453	2.5	11
13	High-throughput cellular screening of engineered nuclease activity using the single-strand annealing assay and luciferase reporter. *Methods in Molecular Biology*, **2014**, 1114, 339-52	1.4	10
12	Engineering imaging probes and molecular machines for nanomedicine. *Science China Life Sciences*, **2012**, 55, 843-61	8.5	8
11	Controlling gene expression in Drosophila using engineered zinc finger protein transcription factors. *Biochemical and Biophysical Research Communications*, **2006**, 348, 873-9	3.4	7
10	Codon swapping of zinc finger nucleases confers expression in primary cells and in vivo from a single lentiviral vector. *Current Gene Therapy*, **2014**, 14, 365-76	4.3	7
9	Designing and testing the activities of TAL effector nucleases. *Methods in Molecular Biology*, **2014**, 1114, 203-19	1.4	5
8	331. Development of Neisseria meningitidis CRISPR/Cas9 Systems for Efficient and Specific Genome Editing. *Molecular Therapy*, **2015**, 23, S132-S133	11.7	4
7	Identification of off-target cleavage sites of zinc finger nucleases and TAL effector nucleases using predictive models. *Methods in Molecular Biology*, **2014**, 1114, 371-83	1.4	4
6	Crispr/Cas9- Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies. *Blood*, **2016**, 128, 3623-3623	2.2	3
5	Gene Editing with Crispr-Cas9 for Treating Beta-Hemoglobinopathies. *Blood*, **2015**, 126, 3376-3376	2.2	2
4	Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia. *Blood*, **2016**, 128, 4708-4708	2.2	2
3	Cellular Therapies: Gene Editing and Next-Gen CAR T Cells **2016**, 203-247		1
2	genome editing at the albumin locus to treat methylmalonic acidemia.. *Molecular Therapy - Methods and Clinical Development*, **2021**, 23, 619-632	6.4	0
1	Base Editors Flex Sights on Sickle-Cell Disease. *CRISPR Journal*, **2021**, 4, 166-168	2.5	